Cytosorbents Corp 8-K

What Happened
Cytosorbents Corporation announced in a Form 8-K (filed April 2, 2026) that Nasdaq’s Listing Qualifications Staff granted a 180‑day extension on April 1, 2026 for the company to regain compliance with the $1.00 minimum bid price requirement. The new compliance deadline is September 28, 2026. The Extension Notice follows an earlier Nasdaq notice (dated October 2, 2025) that found the company out of compliance based on its closing bid price; the original cure period expired March 31, 2026.

Key Details

• Nasdaq Listing Rule at issue: Rule 5550(a)(2) — minimum bid price $1.00 per share.
• Cure condition: the common stock must close at $1.00 or more for at least 10 consecutive trading days to regain compliance.
• Dates: Extension Notice received April 1, 2026; new deadline September 28, 2026 (180 days).
• Company actions: extension has no immediate effect on listing or SEC reporting; the company is monitoring the bid price and may consider actions such as a reverse stock split. The filing states there is no assurance compliance will be regained.

Why It Matters
Investors should note the company remains at risk of delisting from Nasdaq if it does not meet the $1.00 bid requirement within the extended period. Delisting could affect liquidity, trading, and certain investors’ ability to hold the stock. The company’s mention of possible measures (for example, a reverse stock split) signals management may take steps that would change share count and per‑share price to try to meet Nasdaq rules. The Extension Notice itself does not change current listing status or SEC reporting obligations.